The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Open accessAbstract
Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9].
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Murphy, G. J., Reeves, B. C., Rogers, C. A., Rizvi, S. I. A., Culliford, L., & Angelini, G. D. (2007) · Circulation · doi:10.1161/circulationaha.107.698977 · Cited by 1,371
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Carson, J. L., Stanworth, S. J., Roubinian, N., Fergusson, D. A., Triulzi, D., Doree, C., & Hebert, P. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002042.pub4 · Cited by 1,250
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Self-citationLudwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.019 · Cited by 925
Self-citation
Research works printed but not linked: 24
- Delarue, 2013, Iron parameters and relation to prognosis in elderly patients with aggressive lymphoma receiving first line immunochemotherapy: an analysis of the Lysa LNH 03-6B Study, Blood, 122
- Hudis, 2004, rHuEPO and treatment outcomes: the clinical experience, Oncologist, 9, 55, 10.1634/theoncologist.9-90005-55 · doi:10.1634/theoncologist.9-90005-55
- Aapro, 2016, Practical recommendations for the treatment of anemia in cancer patients, Malignant Tumors, 4, 368
- Hedenus, 2003, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study, Br J Haematol, 122, 394, 10.1046/j.1365-2141.2003.04448.x · doi:10.1046/j.1365-2141.2003.04448.x
- Aapro, 2009, An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology, Oncologist, 14, 1, 10.1634/theoncologist.2009-S1-1 · doi:10.1634/theoncologist.2009-s1-1
- Cazzola, 1995, Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response, Blood, 86, 4446, 10.1182/blood.V86.12.4446.bloodjournal86124446 · doi:10.1182/blood.v86.12.4446.bloodjournal86124446
- Moebus, 2013, Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial, J Nat Cancer Inst, 105, 1018, 10.1093/jnci/djt145 · doi:10.1093/jnci/djt145
- Aapro, 2015, Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis, Ann Oncol, 26, 688, 10.1093/annonc/mdu579 · doi:10.1093/annonc/mdu579
- Galli, 2004, Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma, Haematologica, 89, 1141
- Hastka, 1994, Central role of zinc protoporphyrin in staging iron deficiency, Clin Chem, 40, 768, 10.1093/clinchem/40.5.768 · doi:10.1093/clinchem/40.5.768
- Aapro, 2011, Too-low iron doses and too many dropouts in negative iron trial?, J Clin Oncol, 29, e525, 10.1200/JCO.2011.35.3219 · doi:10.1200/jco.2011.35.3219
- Jaspers, 2015, Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation, Am J Hematol, 90, e133, 10.1002/ajh.24013 · doi:10.1002/ajh.24013
- Rezazadeh, 2005, Evidence that iron overload plus croton oil induce skin tumours in mice, Hum Exp Toxicol, 24, 409, 10.1191/0960327105ht544oa · doi:10.1191/0960327105ht544oa
- Link, 2013, Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany, Onkologie, 36, 266
- Osterborg, 1998, Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?, Med Oncol, 15, S47
- Upile, 2009, Blood product transfusion and cancer prognosis, Clin Adv Hematol Oncol, 7, 656
- Halabi, 2013, Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis, Am J Surg, 206, 1024, 10.1016/j.amjsurg.2013.10.001 · doi:10.1016/j.amjsurg.2013.10.001
- Carson, 2014, Should we universally adopt a restrictive approach to blood transfusion? It's all about the number, Am J Med, 127, 103, 10.1016/j.amjmed.2013.10.026 · doi:10.1016/j.amjmed.2013.10.026
- Sanon, 2011, Peripheral arterial ischemic events in cancer patients, Vasc Med, 16, 119, 10.1177/1358863X10388346 · doi:10.1177/1358863x10388346
- Weise, 2012, Biosimilars: what clinicians should know, Blood, 120, 5111, 10.1182/blood-2012-04-425744 · doi:10.1182/blood-2012-04-425744
- Ferro, 2012, Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies, Kidney Int, 81, 1273, 10.1038/ki.2012.22 · doi:10.1038/ki.2012.22
- Krivoshiev, 2008, Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia, Curr Med Res Opin, 24, 1407, 10.1185/030079908X297402 · doi:10.1185/030079908x297402
- Haag-Weber, 2009, Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis, Clin Nephrol, 72, 380
- Weigang-Köhler, 2009, HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours, Oncol Res Treat, 32, 168, 10.1159/000200783 · doi:10.1159/000200783
Cited by
Cancer-Related Fatigue: Causes and Current Treatment Options
Thong, M. S. Y., van Noorden, C. J. F., Steindorf, K., & Arndt, V. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0707-5 · Cited by 438
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
Soetaert, F., Korangath, P., Serantes, D., Fiering, S., & Ivkov, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.025 · Cited by 406
Saad, F., Clarke, N. W., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00382-0 · Cited by 326
Iron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151
Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation
Gómez-Ramírez, S., Brilli, E., Tarantino, G., & Muñoz, M. (2018) · Pharmaceuticals · doi:10.3390/ph11040097 · Cited by 132
Metadata
- Authors
- Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Österborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., Jordan, K., & Herrstedt, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Issue
- Suppl 4
- Pages
- iv96-iv110
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2894700795
- Cited by
- 288
- References
- 136
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 463 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1093/annonc/mdx758
- The paper
- Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Österborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., Jordan, K., & Herrstedt, J. (2018). Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. https://doi.org/10.1093/annonc/mdx758
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.